Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

33° Cloudy
- Bishop, CA (93514)
  Today
  
  Rain. High near 45F. Winds SSW at 5 to 10 mph. Chance of rain 90%. Rainfall around a quarter of an inch..
  
  Tonight
  
  Some clouds. Low 32F. Winds light and variable.
  
  Updated: November 18, 2025 @ 6:03 am
- Full Forecast

Site search

Home
News
Sports
Obituaries
e-Edition
Special Sections
Classifieds
- Place an ad
Archives

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

708.36 +4.05 (+0.58%)

Streaming Delayed Price Updated: 9:46 AM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

57 58 Next >

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

June 28, 2023

From The Schall Law Firm

Via Business Wire

Why Regeneron Stock Is Trading Lower Today ↗

June 28, 2023

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License...

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

June 28, 2023

Via Benzinga

Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

June 28, 2023

Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%...

Via Benzinga

Where Regeneron Pharmaceuticals Stands With Analysts ↗

June 27, 2023

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

June 22, 2023

Via Benzinga

18 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

June 09, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023 ↗

June 28, 2023

Via Benzinga

Why Regeneron Stock Is Falling Today ↗

June 27, 2023

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of...

Via Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years ↗

June 07, 2023

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity For June 05 ↗

June 05, 2023

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity ↗

May 30, 2023

Via Benzinga

Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71% ↗

May 26, 2023

Via Benzinga

Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender ↗

June 27, 2023

The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday.

Via Investor's Business Daily

Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema

June 27, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler

June 27, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead ↗

June 26, 2023

After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks.

Via Talk Markets

Regeneron Pharmaceuticals Unusual Options Activity For May 25 ↗

May 25, 2023

Via Benzinga

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

May 22, 2023

Via Benzinga

Biotech And Healthcare Stocks Lagging ↗

June 21, 2023

Healthcare is a laggard with XLV down YTD but UNH is still a core position.

Via Talk Markets

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

June 21, 2023

Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.

Via The Motley Fool

How to Retire Rich: Biotech Stocks Edition ↗

June 18, 2023

Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.

Via InvestorPlace

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 ↗

June 14, 2023

JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and

Via Benzinga

2 Stocks to Buy No Matter What Happens in June and Beyond ↗

June 14, 2023

A lot could go wrong in the next few months, but investors should largely ignore all that noise.

Via The Motley Fool

3 Biotech Stocks to Sell in June Before They Crash and Burn ↗

June 06, 2023

Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them.

Via InvestorPlace

Wall Street Says These 2 Stocks May Double. Should You Buy Them? ↗

June 05, 2023

Both of these stocks have declined over the past year.

Via The Motley Fool

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

May 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations

May 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

A Good Week For The Market But A Pause In The Biotech Rally ↗

May 22, 2023

Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.

Via Talk Markets

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Local Events
Obituaries
Multimedia
Online Features
Announcements

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

Contact Information

InyoRegister.com
407 W. Line St. #8
Bishop, CA 93514
Phone: 760-873-3535

Advertising

Retail Sales: egalanski@inyoregister.com
Classified Sales: classy@inyoregister.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Bishop, CA (93514)

Today

Tonight

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Sections

Services

Contact Information